Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4096931 | 0.81 | SLC9A1 (0.36) | DAOALDH1A1HSD17B10 | |
| SCHEMBL3294049 | 0.69 | KMT2A (0.35) | DAOALDH1A1KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL28360828 | 0.69 | LMNA (0.32) | — | |
| SCHEMBL22025584 | 0.69 | MAPT (0.37) | DAOALDH1A1KDM4E | |
| SCHEMBL7140395 | 0.68 | AKR1C3 (0.42) | ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL11605593 | 0.68 | PTGS2 (0.46) | ALDH1A1KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL28560116 | 0.68 | LIMK1 (0.43) | KDM4E | |
| Hydrochloric Acid SCHEMBL28531727 | 0.68 | MAPT (0.49) | ALDH1A1KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL20430542 | 0.66 | PRSS1 (0.32) | — | |
| Formamide SCHEMBL4205324 | 0.65 | MAPT (0.46) | ALDH1A1KDM4ESMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107820494-B | Nuclear receptor modulators | 艾伯维公司 | 2020-10-16 | — | — | CN | disclosed |
| US-20190055196-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2019-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055196-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | DAO 4755/4885ALDH1A1 940/4885KDM4E 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.